AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, We wish to inform you that ICRA Limited has reaffirmed credit rating on commercial paper and term loan and assigned credit rating on Long term- Fund based term loan, Long term- Fund based CC and Short term- Fund based/Non-fund based facilities of the company. Aarti Drugs Ltd - 524348 - Compliance Of Regulation 40(10) Of SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2021
We are forwarding herewith Certificate under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 received from Jagdish Patel & Co., Practicing Company Secretary, for the half year ended March 31, 2021 for your perusal and record. Aarti Drugs Ltd - 524348 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclose herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2021 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. AARTI DRUGS LTD. - 524348 - Shareholding for the Period Ended March 31, 2021
Aarti Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here AARTI DRUGS LTD. - 524348 - Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 AARTI DRUGS LTD. - 524348 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 2350 Name of the Signatory :- Rushikesh DeoleDesignation :- Company Secretary and Compliance Officer Aarti Drugs Ltd - 524348 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 2350 Name of the Signatory :- Rushikesh DeoleDesignation :- Company Secretary and Compliance Officer Aarti Drugs Ltd - 524348 - Closure of Trading Window
This is to inform that the Trading Window of the Company will remain closed from Thursday, April 1, 2021 until the expiry of 48 hours after the declaration of Financial Results of the Company for the quarter and year ended March 31, 2021. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. We wish to inform you that ICRA Limited has assigned credit rating on the bank facilities of the Company. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Filing of Public Announcement for Buyback of Fully Paid -up Equity Shares of Aarti Drugs Limited pursuant to the provisions of Regulation 7(i) of SEBI (Buyback of Securities) Regulations, 2018, as amended ('Buyback Regulation')